Nevertheless, whether these drugs could exert therapeutic effects on breast cancer by inhibiting the over-expression of RRM2, CDK1 and CCNA2, or whether CCNB2, BUB1B and CDC20 are promising therapeutic targets still need to be supported by further research. The gene discussed is CDC20; the disease is breast carcinoma.